Build the Launch, Then Cut the Deal: A Smarter Playbook for Emerging Biotech Value

For emerging and late-stage biotechs, out-licensing is often viewed as the safer path. Data from our five-year analysis of real-world licensing deal outcomes tells a different story.

In this paper, EVERSANA experts break down two critical decisions: 

1. Out-license vs. launch independently? 
2. If the former, at which stage will out-licensing maximize transactional value? 

Our experts dive into the key launch and licensing paths that biotechs consider, revealing when commercialization becomes your strongest leverage for long-term value creation.

“Data consistently shows that companies launching and commercializing their own products achieve market capitalizations more than 6x higher than those that rely solely on licensing.”